Polio Vaccines Market Size by Product, Type, Region, Industry-Wide Analysis, Competitive Landscape Assessment & Long-Term Forecast to 2032
Overview
Polio Vaccines Market was valued at USD 836.95 Mn in 2025 and the Global Polio Vaccines Market is expected to reach USD 1043.41 Mn by 2032 at a CAGR of 3.2% during forecast period.
Polio Vaccines Market Overview:
The polio vaccine is a biological product that is used against poliomyelitis (polio), a viral infection that results in paralysis of a person. Polio usually occurs in children between the age of 5 to 7. Up to 70%-72% of all polio infections among children are symptomless so therefore, the investments in next-generation polio vaccine R&D, such as new IPV and nOPV2, are driving innovation and it helping to identify polio that are symptomless. Such funding efforts are helping to increase production capacity, availability, and market size of the polio vaccine market, whereas the Next-generation vaccines, such as next-gen IPV and nOPV2, promise better safety and efficacy that minimise risks that is related to vaccine-derived poliovirus. Their development creates new market opportunities for expansion, particularly in areas that are concentrating on eradication.
North America region led the Polio Vaccine Market due to its high awareness among the population in the region and due to good healthcare infrastructure and high vaccination rates. The public confidence in immunisation and repeated education campaigns has maintained high demand. The Well-established firms and companies like Pfizer Inc. and GlaxoSmithKline (GSK) lead the market as they have strong vaccine portfolios, R&D expenditures, and secure supply chains which help to grow the market. Trends such as IPV revenue leadership and OPV's robust growth are driving product segmentation in the market. Local manufacturing and AI-driven distribution improvements are boosting access, efficiency, and regional market growth.
The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding the global polio vaccines market dynamics, structure by identifying and analyzing the market segments and project the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTER’s analysis, and SWOT analysis to address questions of shareholders to prioritizing the efforts and investment in the near future to the emerging segment in the global polio vaccines market.
To know about the Research Methodology :- Request Free Sample Report
Polio Vaccine Market Dynamics
Investments for Polio Vaccine Development to Drive the Polio Vaccine Market
Polio vaccine industry growth is anticipated to accelerate over the next five years, driven by an rising in investments for the development of different types of polio vaccines. The global polio vaccines market has witnessed significant progress over the past few years because of the increased effort to eradicate polio across the world. According to the Global Eradication Polio Initiative, more than 15Mn cases of polio have been prevented by the oral polio vaccine, and eradication of polio has been achieved in most target countries.
An advanced vaccine to create the opportunity for the polio vaccine market
This polio vaccine is undergoing substantial changes with the shift from the traditional OPV to more advanced types like the next-generation IPV and nOPV2. The postulated goal of this transition is to lessen the risks of VDPV, which arise in live-attenuated OPV strains in some circumstances. The next-gen IPVs provide safe, non-replicating protection, and the nOPV2s are genetically stabilised to thwart reversion in epidemic scenarios.
Vaccine Misinformation to restrain the Polio Vaccine Market
Misinformation about the vaccine creates the downfall for the market and for the companies. In countries like Pakistan and Afghanistan, people believe that the polio vaccine was made to reduce the muslim population and to reduce the birth rates. Also, many rumours said that the vaccine contains pork-derived ingredients or alcohol this misleading or incorrect information, restrain the market.
Polio Vaccine Market Segment Analysis
Based on the product, the Polio Vaccine Market is segmented into Hospital, Clinics, Public Services and Others. In this Public services segment dominated the market in 2025 and is expected to dominate the market in the forecast period, also due to the increased public immunisation programs as a result of public health concerns. Projects undertaken by the World Health Organisation (WHO), UNICEF, and the Vaccine Alliance and they have increased large-scale immunisation rates, particularly in lower and middle-income countries.
Based on the Type, the Polio Vaccine Market is segmented into Inactivated Polio Vaccine (IPV) and Oral Polio Vaccine (OPV). In this Inactivated Polio Vaccine dominated the market in 2025 and is expected to dominate the market in the forecast period also as there is high demand to enhance the safety and efficacy of immunisation. The Inactivated Polio Vaccine is an inactivated (killed) virus administered via injection, eliminates the risk of the virus-causing disease because it stimulates an immunological response.
The Oral Polio Vaccine (OPV) segment is leading the global polio Vaccines market. One trend affecting the polio vaccine market is the cessation of the oral polio vaccine. There is a growing need for cessation of OPV as the use of OPV can result in cases of polio owing to circulating VDPV and vaccine-associated paralytic polio, as oral vaccines contain weakened polioviruses.
Polio Vaccine Market Recent Developments
| Date | Company / Organization | Development | Impact |
|---|---|---|---|
| 13 February 2026 | Biological E. Limited | The World Health Organization granted official prequalification status to Biological E.'s novel oral polio vaccine type 2 (nOPV2), utilizing in-house bulk technology transferred from Indonesia's PT Bio Farma. | This milestone establishes the company as the world's second full manufacturer of nOPV2, adding 600 million doses per year to secure the global outbreak response supply chain. |
| 13 October 2025 | Global Polio Eradication Initiative (GPEI) | The GPEI officially launched its 2026 Action Plan, outlining structural shifts to scale up the administration of fractional-dose inactivated polio vaccines (fIPV) and nOPV2 within high-risk geographies. | The streamlined operational blueprint addresses a critical 30% funding reduction while maintaining intensive immunization efforts to completely interrupt variant poliovirus transmission. |
| 12 July 2025 | WHO / UNICEF | The World Health Organization and UNICEF, in collaboration with Yemen's Ministry of Public Health, initiated a massive emergency polio vaccination drive deploying the novel oral polio vaccine type 2 (nOPV2). | The emergency response deployed nearly 7,000 healthcare teams to immunize more than 1.3 million children across 120 conflict-affected districts to suppress variant type 2 poliovirus. |
| 01 April 2025 | Johnson & Johnson | Johnson & Johnson advanced its upstream manufacturing processes for a Sabin-strain inactivated polio vaccine (sIPV) by leveraging innovative fixed-bed bioreactor technology. | The optimization achieves higher cell densities and viral yields, substantially boosting production scalability and economic feasibility for next-generation, non-replicating polio vaccines. |
Polio Vaccine Market Regional Analysis
The North America region dominated the Polio Vaccine Market due to High Public Awareness & Vaccination Rates
North Americans dominated the region in 2025 and is expected to dominate in the upcoming years as well as they do campaigns and because of that there is high public awareness about polio and much higher vaccine coverage; chronic public-health education and communication strategies that have contributed to this and there is strong culture of trust in medical science. Numerous educational campaigns have been run by government agencies, medical providers, and community organisations to educate the public on the value of immunisation, especially against diseases that can cause death, such as polio. Further to that, the public's environment conducive to confidence was matured through accesses to the previous successes of vaccination programs and transparency in health policies, which consequently distributed the widespread and timely acceptance of technologies for polio vaccines throughout the continent.
Polio Vaccine Market Competitive Analysis
Top companies like Pfizer Inc., GlaxoSmithKline / GSK, Serum Institute of India, Biovac Institute and Bio-Manguinhos / Fiocruz hold the largest share in the Polio Vaccine Market. Whereas companies like Pfizer Inc. and GlaxoSmithKline / GSK stand out due to their operational and technological advantages. GSK provides Inactivated Poliovirus Vaccine (IPV) and combination vaccines such as Infanrix Hexa (DTaP-HBV-IPV/Hib), as it protects against six diseases, whereas Pfizer Inc. includes IPV and contributes to polio immunisation programs via government and NGO collaborations. they focus 60% on R&D and public health collaboration. Both companies invest in new vaccine technologies, adjuvants (like GSK’s AS01), and platform scalability that support next-gen polio and combination vaccines.
Polio Vaccines Market Key Trends
• Product Segmentation & Innovation- IPV (inactivated polio vaccine) leads in revenue; OPV (oral vaccine) grows fastest due to low cost and ease of administration.
• Manufacturing, Supply Chain & Local Production- Strategic partnerships are expanding regional manufacturing, e.g., Sanofi & Biovac in Africa produce IPV locally.
• Digital Health & Distribution Innovations- AI/ML enhance outbreak prediction, distribution route optimisation, cold-chain tracking, and targeting low uptake areas.
Polio Vaccines Market Scope: Inquire before buying
| Polio Vaccines Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2025 | Forecast Period: | 2026-2032 |
| Historical Data: | 2020 to 2025 | Market Size in 2025: | USD 836.95 Mn. |
| Forecast Period 2026 to 2032 CAGR: | 3.2% | Market Size in 2032: | USD 1043.41 Mn. |
| Segments Covered: | by Product | Hospital Clinics Public Services Others |
|
| by Type | Inactivated Polio Vaccine (IPV) Oral Polio Vaccine (OPV) |
||
Polio Vaccines Market by Region
North America (United States, Canada, and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, and the Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Taiwan, Indonesia, Philippines, Malaysia, Vietnam, Thailand, Rest of Asia Pacific region)
Middle East & Africa (South Africa, GCC, Nigeria, Rest of ME&A)
South America (Brazil, Argentina, Rest of South America)
Polio Vaccines Market Key Players
North America
1. Pfizer Inc. (New York, United States)
2. Johnson & Johnson (New Brunswick, New Jersey, United States)
3. Merck & Co. (Kenilworth, New Jersey, United States)
4. Emergent BioSolutions, Inc. (Gaithersburg, Maryland, United States)
5. AbbVie Inc. (North Chicago, Illinois, United States)
Europe
6. GlaxoSmithKline / GSK (Brentford, United Kingdom)
7. Sanofi (Paris, France)
8. Novartis AG (Basel, Switzerland)
Asia Pacific
9. Serum Institute of India (Pune, India)
10. Bharat Biotech (Hyderabad, India)
11. Panacea Biotec Ltd (New Delhi, India)
12. Bio-Med (Ghazabad, Uttar Pradesh, India)
13. Bibcol (Bharat Immunologicals and Biologicals Corporation Ltd.) (Bulandshahr, Uttar Pradesh, India)
14. Halfkin Bio-Pharmaceuticals (Pune, India)
15. IMBCA (Indian Immunologicals Ltd - IMBC Division) (Hyderabad, India)
16. Tiantan Biological Products Co., Ltd. (Beijing, China)
17. Astellas Pharma Inc. (Tokyo, Japan)
18. CSL Limited (Melbourne, Australia)
Middle East & Africa
19. Biovac Institute (Cape Town, South Africa)
20. Vacsera(Giza, Egypt)
21. Institut Pasteur de Tunis (Tunisia)
22. Pasteur Institute of Iran (Iran)
South America
23. Bio-Manguinhos / Fiocruz (Brazil)
24. Instituto Butantan (Brazil)
25. ANLIS-Malbrán (Argentina)
26. Colombian National Institute of Health (INS – Instituto Nacional de Salud) (Colombia)
Frequently Asked Questions:
1] What segments are covered in the Global Polio Vaccines Market report?
Ans. The segments covered in the Market report are based on Software Deployment, Type, End-user, and Application.
2] Which region is expected to hold the highest share in the Global Market?
Ans. The North American region is expected to hold the highest share in the Market.
3] What is the market size of the Global Polio Vaccines Market by 2032?
Ans. The global market size is expected to reach USD 1043.41 Million by 2032.
4] What is the forecast period for the Global Polio Vaccines Market?
Ans. The forecast period for the Global Market is 2026-2032.
5] What was the market size of the Global Polio Vaccines Market in 2025?
Ans. The market size of the Global Market in 2025 was valued at USD 836.95 Mn.